Literature DB >> 25966981

Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art.

Barbara Vanhoecke1, Emma Bateman2, Bronwen Mayo3, Eline Vanlancker4, Andrea Stringer5, Daniel Thorpe6, Dorothy Keefe7.   

Abstract

Mucositis is a major oncological problem. The entire gastrointestinal and genitourinary tract and also other mucosal surfaces can be affected in recipients of radiotherapy, and/or chemotherapy. Major progress has been made in recent years in understanding the mechanisms of oral and small intestinal mucositis, which appears to be more prominent than colonic damage. This progress is largely due to the development of representative laboratory animal models of mucositis. This review focuses on the development and establishment of the Dark Agouti rat mammary adenocarcinoma model by the Mucositis Research Group of the University of Adelaide over the past 20 years to characterize the mechanisms underlying methotrexate-, 5-fluorouracil-, and irinotecan-induced mucositis. It also aims to summarize the results from studies using different animal model systems to identify new molecular and cellular markers of mucositis.
© 2015 by the Society for Experimental Biology and Medicine.

Entities:  

Keywords:  5-fluorouracil; Rat; chemotherapy; irinotecan; methotrexate; mucositis

Mesh:

Substances:

Year:  2015        PMID: 25966981      PMCID: PMC4935219          DOI: 10.1177/1535370215581309

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  146 in total

1.  Contributions of mucosal immune cells to methotrexate-induced mucositis.

Authors:  Barbara A E de Koning; Jolanda M van Dieren; Dicky J Lindenbergh-Kortleve; Maria van der Sluis; Tetsuya Matsumoto; Keizo Yamaguchi; Alexandra W Einerhand; Janneke N Samsom; Rob Pieters; Edward E S Nieuwenhuis
Journal:  Int Immunol       Date:  2006-04-24       Impact factor: 4.823

2.  Epithelial hedgehog signals pattern the intestinal crypt-villus axis.

Authors:  Blair B Madison; Katherine Braunstein; Erlene Kuizon; Kathleen Portman; Xiaotan T Qiao; Deborah L Gumucio
Journal:  Development       Date:  2004-12-08       Impact factor: 6.868

3.  5-FU-induced apoptosis correlates with efficacy against human gastric and colon cancer xenografts in nude mice.

Authors:  T Inada; A Ichikawa; T Kubota; Y Ogata; A R Moossa; R M Hoffman
Journal:  Anticancer Res       Date:  1997 May-Jun       Impact factor: 2.480

Review 4.  Intestinal brush border glycohydrolases: structure, function, and development.

Authors:  E H Van Beers; H A Büller; R J Grand; A W Einerhand; J Dekker
Journal:  Crit Rev Biochem Mol Biol       Date:  1995       Impact factor: 8.250

5.  Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the Dark Agouti rat.

Authors:  Noor Al-Dasooqi; Joanne M Bowen; Rachel J Gibson; Richard M Logan; Andrea M Stringer; Dorothy M Keefe
Journal:  Int J Exp Pathol       Date:  2011-04-05       Impact factor: 1.925

6.  Effects of perturbations of pools of deoxyribonucleoside triphosphates on expression of ribonucleotide reductase, a G1/S transition state enzyme, in p53-mutated cells.

Authors:  S Wadler; R Horowitz; H Y Zhang; E L Schwartz
Journal:  Biochem Pharmacol       Date:  1998-05-01       Impact factor: 5.858

Review 7.  C-reactive protein as a marker for inflammatory bowel disease.

Authors:  Séverine Vermeire; Gert Van Assche; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2004-09       Impact factor: 5.325

8.  Oral trefoil peptides protect against ethanol- and indomethacin-induced gastric injury in rats.

Authors:  M W Babyatsky; M deBeaumont; L Thim; D K Podolsky
Journal:  Gastroenterology       Date:  1996-02       Impact factor: 22.682

9.  Platelet-activating factor induces the processing of nuclear factor-kappaB p105 into p50, which mediates acute bowel injury in mice.

Authors:  Shirley X L Liu; Runlan Tian; Heather Baskind; Wei Hsueh; Isabelle G De Plaen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-05-21       Impact factor: 4.052

10.  Combined intestinal trefoil factor and epidermal growth factor is prophylactic against indomethacin-induced gastric damage in the rat.

Authors:  R Chinery; R J Playford
Journal:  Clin Sci (Lond)       Date:  1995-04       Impact factor: 6.124

View more
  5 in total

1.  Luteolin prevents irinotecan-induced intestinal mucositis in mice through antioxidant and anti-inflammatory properties.

Authors:  Thaise Boeing; Priscila de Souza; Silvia Speca; Lincon Bordignon Somensi; Luisa Nathália Bolda Mariano; Benhur Judah Cury; Mariana Ferreira Dos Anjos; Nara Lins Meira Quintão; Laurent Dubuqoy; Pierre Desreumax; Luisa Mota da Silva; Sérgio Faloni de Andrade
Journal:  Br J Pharmacol       Date:  2020-02-15       Impact factor: 8.739

2.  The effect of hippophae rhamnoides extract on oral mucositis induced in rats with methotrexate.

Authors:  Ozan Kuduban; Muhammed Recai Mazlumoglu; Selma Denktas Kuduban; Ertugrul Erhan; Nihal Cetin; Osman Kukula; Oguzhan Yarali; Ferda Keskin Cimen; Murat Cankaya
Journal:  J Appl Oral Sci       Date:  2016 Sep-Oct       Impact factor: 2.698

3.  Development of a self-limiting model of methotrexate-induced mucositis reinforces butyrate as a potential therapy.

Authors:  A R da Silva Ferreira; S A J van der Aa; T Wehkamp; H R Wardill; J P Ten Klooster; J Garssen; L F Harthoorn; A Hartog; H J M Harmsen; W J E Tissing; J van Bergenhenegouwen
Journal:  Sci Rep       Date:  2021-11-25       Impact factor: 4.379

4.  Effect of Hippophae rhamnoides Extract on Oxidative Oropharyngeal Mucosal Damage Induced in Rats Using Methotrexate.

Authors:  Ertugrul Erhan; Suat Terzi; Metin Celiker; Oguzhan Yarali; Murat Cankaya; Ferda Keskin Cimen; Ismail Malkoc; Bahadir Suleyman
Journal:  Clin Exp Otorhinolaryngol       Date:  2016-08-10       Impact factor: 3.372

5.  Use of the Rat Grimace Scale to Evaluate Visceral Pain in a Model of Chemotherapy-Induced Mucositis.

Authors:  Rebecca P George; Gordon S Howarth; Alexandra L Whittaker
Journal:  Animals (Basel)       Date:  2019-09-12       Impact factor: 2.752

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.